Clinical trials: Acute Antibody-Mediated Rejection (AMR)

Kidney Transplant Rejection, Antibody-mediated Rejection

Transplant Antibody-Mediated Rejection: Guiding Effective Treatments

• Terminated
• Age: 5 years and older
• Phase 3
• Injection or infusion
• Surgery or procedure

This trial evaluates the addition of rituximab to standard of care in the treatment of antibody-mediated rejection in kidney transplant patients. The trial will involve adults and children.

Trial name

TAR:GET-1 (NCT03994783)

Testing

Rituximab, Methylprednisolone, Intravenous Immunoglobulin

Where

United Kingdom

Volunteers

3 people

Sponsor

Imperial College London